A randomized, double-blind, placebo-controlled trial of IL-7 in critically ill patients with COVID-19
Manu Shankar‐Hari(Centre for Inflammation Research), Richard S. Hotchkiss(Washington University in St. Louis), Marcel R.M. van den Brink(City Of Hope National Medical Center), Michel Morre, James P. Bosanquet(Missouri Baptist Medical Center), Andrew H. Walton(Washington University in St. Louis), Frederique Berbille, Cassian Yee(The University of Texas MD Anderson Cancer Center), Robert Martin(Missouri Baptist Medical Center), Vidula Vachharajani(Cleveland Clinic), Thomas Daix, Stephen M. Pastores(Memorial Sloan Kettering Cancer Center), Teresa Blood(Washington University in St. Louis), David A. Striker(Missouri Baptist Medical Center), Robin Jeannet(Hôpital Universitaire Dupuytren), Reinaldo Salomão(Universidade Federal de São Paulo), Felipe Dal‐Pizzol(Universidade do Sul de Santa Catarina), Lyle L. Moldawer(University of Florida), Kenneth E. Remy(Washington University in St. Louis), Scott C. Brakenridge(University of Florida), Cristina Gutiérrez(The University of Texas MD Anderson Cancer Center), Bruno François(Inserm), Nitin J. Anand(Missouri Baptist Medical Center), Georg Auzinger(King's College - North Carolina), Jane Blood(Washington University in St. Louis)
Cited by 21
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Genomic responses in mouse models poorly mimic human inflammatory diseases
|Proceedings of the National Academy of Sciences|2013|3k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Sepsis and septic shock
|Nature Reviews Disease Primers|2016|1.6k
Assessment of the worldwide burden of critical illness: the Intensive Care Over Nations (ICON) audit
|The Lancet Respiratory Medicine|2014|1.3k